NCNA
NuCana plc
$2.04
+3.03%
$8.2M
No data for this timeframe.
Vol
Market Cap$8.2M
Cap SizeNano Cap
Inst. Holders1 funds
Inst. Value$378.00
Inst. Activity1 buys / 0 sells
SEC Reports2
Press Releases1
Recent Activity
May 14, 2026
SEC
NuCana reported Q1 2026 results with a net loss of £3.9M, wider than the £2.5M loss in Q1 2025, driven by increased R&D
6-K — Impact 6/10
May 6, 2026
SEC
NuCana published its 2025 UK Annual Report, reporting a net loss of £29.4M vs £19.0M in 2024, driven by a £12.6M non-cas
6-K — Impact 5/10
Apr 15, 2026
Insider
Bruce Theresa Margaret Ms sold 132,600,130 shares
Chief Operating Officer @ $0.00 ($0.00)
Inst.
MORGAN STANLEY — DOUBLED
105 shares ($378.00)
Inst.
UBS Group AG — NEW
10,251 shares ($47.6K)
May 14, 2026
earnings
NuCana Reports First Quarter 2026 Financial Results and Provides Business Update
<p align="center"><strong><em>Final Data from Phase 2 Expansion Study of NUC-7738 Expected in 2026</
Mar 19, 2026
Press
NuCana reported financial results for Q4 and full-year 2025, showing increased net losses but a strengthened cash positi
Impact 6/10
Analyst Ratings
3Strong Buy
3Buy
2Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Aug 19, 2024 | Oppenheimer | REITERATE | Outperform → Outperform |
| Jul 23, 2024 | Oppenheimer | REITERATE | Outperform → Outperform |
| Jul 22, 2024 | Oppenheimer | MAINTAIN | Outperform → Outperform |
| Apr 1, 2024 | Oppenheimer | REITERATE | Outperform → Outperform |
| Nov 21, 2023 | Oppenheimer | REITERATE | Outperform → Outperform |
Latest Reports
BULLISH
6-K
6/10
NuCana reported Q1 2026 results with a net loss of £3.9M, wider than the £2.5M loss in Q1 2025, driven by increased R&D
May 14, 2026
BEARISH
6-K
5/10
NuCana published its 2025 UK Annual Report, reporting a net loss of £29.4M vs £19.0M in 2024, driven by a £12.6M non-cas
May 6, 2026
MIXED
Press
6/10
NuCana reported financial results for Q4 and full-year 2025, showing increased net losses but a strengthened cash positi
Mar 19, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| MORGAN STANLEY | $378.00 | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 15, 2026 | Bruce Theresa | A | $0.00 |
1 institutional holders with $378.00 total value (105 shares) as of 2025-Q4. Top holders: MORGAN. Net buying activity: 1 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | MORGAN STANLEY | 105 | $378.00 | 100.0% | DOUBLED +5150.0% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | DOUBLED | 2 | 105 | +5150.0% | $378.00 | 2025-Q4 |
| UBS Group AG | NEW | — | 10,251 | — | $47.6K | 2025-Q3 |
| CITADEL ADVISORS LLC | EXIT | 25,003 | 0 | -100.0% | $0.00 | 2025-Q1 |
| MORGAN STANLEY | EXIT | 12,313 | 0 | -100.0% | $0.00 | 2025-Q1 |
| CITADEL ADVISORS LLC | NEW | — | 25,003 | — | $29.8K | 2024-Q4 |
| MORGAN STANLEY | DOUBLED | 5,044 | 12,313 | +144.1% | $14.7K | 2024-Q4 |
| UBS Group AG | NEAR_EXIT | 12,604 | 6 | -100.0% | $7.00 | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 16,818 | 0 | -100.0% | $0.00 | 2024-Q4 |
| MORGAN STANLEY | DOUBLED | 1,564 | 5,044 | +222.5% | $11.6K | 2024-Q3 |
1 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 15, 2026 | Bruce Theresa Margaret Ms | Chief Operating Officer | A | 132,600,130 | $0.00 | $0.00 |
2 SEC filing reports analyzed. Sentiment: 1 bullish, 1 bearish, 0 mixed, 0 neutral. Avg impact: 5.5/10.
Historical analyst distribution (last covering-analyst action Aug 2024): 75% buy across 8 analysts — 3 strong buy, 3 buy, 2 hold, 0 sell, 0 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q 2025-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2025-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
7 analyst firms have rated this stock: 0 upgrades, 1 downgrades, 6 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Aug 19, 2024 | Oppenheimer | REITERATE | Outperform | Outperform |
| Jul 23, 2024 | Oppenheimer | REITERATE | Outperform | Outperform |
| Jul 22, 2024 | Oppenheimer | MAINTAIN | Outperform | Outperform |
| Apr 1, 2024 | Oppenheimer | REITERATE | Outperform | Outperform |
| Nov 21, 2023 | Oppenheimer | REITERATE | Outperform | Outperform |
| Sep 6, 2023 | Truist Securities | REITERATE | Buy | Buy |
| Aug 18, 2023 | Oppenheimer | REITERATE | Outperform | Outperform |
| May 22, 2023 | Oppenheimer | REITERATE | Outperform | Outperform |
| Sep 22, 2022 | Jefferies | MAINTAIN | — | Buy |
| Mar 3, 2022 | Cowen & Co. | DOWNGRADE | Outperform | Market Perform |
| Nov 24, 2021 | HC Wainwright & Co. | MAINTAIN | — | Buy |
| Dec 1, 2020 | HC Wainwright & Co. | MAINTAIN | — | Buy |
| Nov 24, 2020 | HC Wainwright & Co. | MAINTAIN | — | Buy |
| Oct 22, 2020 | Truist Securities | INITIATE | — | Buy |
| Aug 21, 2020 | HC Wainwright & Co. | MAINTAIN | — | Buy |
| Jul 24, 2020 | Oppenheimer | INITIATE | — | Outperform |
| Mar 11, 2020 | HC Wainwright & Co. | MAINTAIN | — | Buy |
| Nov 15, 2019 | HC Wainwright & Co. | REITERATE | — | Buy |
| Aug 19, 2019 | HC Wainwright & Co. | INITIATE | — | Buy |
| Oct 19, 2018 | Piper Sandler | INITIATE | — | Overweight |
| Oct 23, 2017 | Citigroup | INITIATE | — | Buy |
| Oct 23, 2017 | Cowen & Co. | INITIATE | — | Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2025 | 3 | 3 | 2 | 0 | 0 | 75% | |
| May 1, 2025 | 3 | 3 | 2 | 0 | 0 | 75% | |
| Apr 1, 2025 | 3 | 3 | 2 | 0 | 0 | 75% | |
| Mar 1, 2025 | 3 | 3 | 3 | 0 | 0 | 67% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 14, 2026
earnings
NuCana Reports First Quarter 2026 Financial Results and Provides Business Update
<p align="center"><strong><em>Final Data from Phase 2 Expansion Study of NUC-7738 Expected in 2026</em></strong></p>
Mar 19, 2026
earnings
NuCana Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Business Update
<p align="center"><strong><em>NUC-7738 Demonstrates Clinical Activity and Favorable Safety in Patients with PD-1 Inhibitor-Resistant Melanoma</em></st
Mar 18, 2026
earnings_calendar
NCNA Q4 2025 Earnings After Market Close — 2026-03-18